DEF: OPKO Health Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

OPKO Health will hold its annual stockholders meeting virtually on April 23, 2025, to vote on director elections, executive compensation, and the ratification of its accounting firm.

Summary

• OPKO Health, Inc. will hold its 2025 Annual Meeting of Stockholders on April 23, 2025, at 10:00 a.m. Eastern Time, conducted virtually via live webcast.
• Stockholders of record as of February 24, 2025, are entitled to vote.
• The meeting will address the election of eleven director nominees, an advisory vote on executive compensation (Say on Pay), and the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• As of February 24, 2025, there were 671,550,270 shares of common stock outstanding, each entitled to one vote.
• The proxy statement and 2024 Annual Report are available online at www.opko.com.
• A nominee for director will be elected if the votes cast in favor of a nominee exceed the votes cast against a nominee.
• The advisory vote on the Say on Pay proposal will be approved if the votes cast in favor of the proposal exceed the votes cast against the proposal.
• The vote to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 will be approved if the votes cast in favor of the proposal exceed the votes cast against the proposal.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting factual information about the upcoming annual meeting and related proposals. The sentiment is neutral to slightly positive due to the routine nature of the information and the board's recommendations for voting.

Positives

• The Board recommends voting FOR the election of all director nominees.
• The Board recommends voting FOR the approval of the Say on Pay proposal.
• The Board recommends voting FOR the ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm.
• Approximately 97% of the votes cast on the advisory vote on the executive compensation proposal at the 2024 annual meeting of stockholders were in favor of our named executive officer compensation as disclosed in the proxy statement, and as a result, our named executive officer compensation was approved by our stockholders.

Future Outlook

The company plans to continue engaging best practices to measure and manage environmental impacts in order to conserve resources, reduce costs, and promote ethical sourcing practices.

Industry Context

The document provides standard information related to corporate governance and shareholder meetings, aligning with typical practices for publicly traded companies. It includes details on director independence, committee structures, and executive compensation, which are common disclosures in the healthcare and pharmaceutical industries.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and stock options, is consistent with industry practices for publicly traded companies of similar size and scope.
• The company's approach to ESG (Environmental, Social, and Governance) is in line with increasing industry trends, focusing on environmental responsibility, social impact, and governance.
• The disclosure of related party transactions is a standard practice to ensure transparency and avoid conflicts of interest, aligning with regulatory requirements and industry norms.
• The company's engagement of Ernst & Young LLP as its independent registered public accounting firm is a common practice among publicly traded companies to ensure financial statement accuracy and compliance.

Related Party Transactions

• The company holds investments in Zebra (ownership 28.5%), ChromaDex Corporation (0.05%), Cocrystal Pharma, Inc. (2%), Non-Invasive Monitoring Systems, Inc. (0.5%), Eloxx Pharmaceuticals, Inc. (1.0%), BioCardia, Inc. (0.3%) and LeaderMed Health Group Limited (47.0%).
• In January 2024, the Company completed a private offering of $230.0 million aggregate principal amount of our 3.75% Convertible Senior Notes due 2029 (the 144A Notes).
• Additionally, the Company issued and sold approximately $71.1 million aggregate principal amount of its 3.75% Convertible Senior Notes due 2029 (the Affiliate Notes and, together with the 144A Notes, the Notes) pursuant to the terms of a note purchase agreement entered into on January 4, 2024 (the Affiliate Note Purchase Agreement) by and among the Company and certain investors including, Frost Gamma Investments Trust, a trust controlled by Phillip Frost, M.D., the Company’s Chairman and Chief Executive Officer, and Jane H. Hsiao, Ph.D., MBA, the Company’s Vice-Chairman and Chief Technical Officer (collectively, the Affiliate Purchasers).
• On October 12, 2023, the Company entered into an E-Commerce Distribution Agreement with NextPlat Corp (NextPlat), a global e-commerce provider, in which Dr. Frost owns more than 20% interest.
• On May 4, 2023, the Company entered into an Assignment and Assumption Agreement (the Assignment Agreement) with Ruen-Hui Biopharmaceuticals, Inc., a Taiwanese entity (Ruen-Hui) in which Dr. Hsiao owns more than a 10% interest.
• We lease office space from Frost Real Estate Holdings, LLC (Frost Holdings) in Miami, Florida, where our principal executive offices are located.
• Dr. Elias Zerhouni, our Vice Chairman and President, sits on the board of directors of Danaher Corporation (Danaher).
• We reimburse Dr. Frost for Company-related use by Dr. Frost and our other executives of an airplane owned by a company that is beneficially owned by Dr. Frost.

Stakeholder Impact

• Shareholders are provided with the opportunity to vote on key company matters, including the election of directors and executive compensation.
• Employees are subject to the company's Code of Business Conduct and Ethics and are encouraged to report any violations.
• The company's commitment to ESG principles may positively impact the environment and communities in which it operates.
• The company's relationships with suppliers and customers are governed by its related party transaction policy to ensure fairness and transparency.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Stockholders on April 23, 2025.
• The Compensation Committee will take into account the outcome of the Say on Pay vote when considering future executive compensation arrangements.
• The company will continue to engage with internal and external stakeholders on ESG topics to help further inform our direction and priorities.

Key Dates